Table 1.
Patient, donor, disease, and transplantation characteristics.
| Non-aGVHD | aGVHD | P value | |
|---|---|---|---|
| N | 47 | 51 | – |
| Patient age | 38 (15-63) | 40 (14-65) | 0.177 |
| Patent sex (M:F) | 25:22 | 26:25 | 0.827 |
| Diagnosis | 0.156 | ||
| ALL | 5 | 14 | |
| AML | 16 | 14 | |
| MDS | 15 | 17 | |
| NHL | 8 | 3 | |
| CML | 3 | 3 | |
| High risk, no. (%) | 12 | 21 | 0.102 |
| Donor source | 0.051 | ||
| MRD | 22 | 15 | |
| Haplo-identical | 17 | 31 | |
| MUD | 8 | 5 | |
| Donor/patient sex | 0.199 | ||
| M–>M | 15 | 8 | |
| M–>F | 12 | 18 | |
| F–>M | 10 | 12 | |
| F–>F | 10 | 13 | |
| Conditioning | 0.439 | ||
| MA | 45 | 51 | |
| RIC | 2 | 0 | |
| GVHD prophylaxis | 0.076 | ||
| MTX + CSA + MMF + ATG | 25 | 36 | |
| MTX + CSA + MMF | 22 | 15 | |
| KIR-L GVH mismatch | 18 | 21 | 0.77 |
| Cell composition in allografts, median (range) | |||
| CD34+ cells, ×106/kg | 6.1 (2.05~16.73) | 5.3 (1.58~12.40) | 0.197 |
| CD3+ cells, ×108/kg | 1.88 (0.43~4.07) | 1.78 (0.35~4.78) | 0.347 |
| CD56+ cells, ×107/kg | 3.38 (0.29~6.45) | 2.68 (0.27~7.10) | 0.059 |
| NK:T ratio | 0.225 (0.051~0.498) | 0.172 (0.049~0.698) | 0.117 |
GVHD, graft-vs.-host disease; F, female; M, male; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; CML, Chronic Myelogenous Leukemia; MRD, matched related donor; MUD, matched unrelated donor; KIR-L, killer Ig-like receptor ligand; NK, natural killer cell; T, T cell.